Literature DB >> 4239995

[Histochemical study of Lafora's bodies].

M Dubois-Dalcq.   

Abstract

Mesh:

Substances:

Year:  1969        PMID: 4239995     DOI: 10.1007/bf00687645

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  29 in total

1.  [PROGRESSIVE MYOCLONIC EPILEPSY AS A THESAURISMOSIS].

Authors:  G W EDGAR
Journal:  Rev Neurol (Paris)       Date:  1963-06       Impact factor: 2.607

2.  DIAMINE METHODS FOR DIFFERENTIALING MUCOSUBSTANCES HISTOCHEMICALLY.

Authors:  S S SPICER
Journal:  J Histochem Cytochem       Date:  1965-03       Impact factor: 2.479

3.  THE RETINAL PATHOLOGY OF LAFORA'S DISEASE: A FORM OF GLYCOPROTEIN-ACID MUCOPOLYSACCHARIDE DYSTROPHY.

Authors:  M YANOFF; G A SCHWARZ
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1965 Jul-Aug

4.  Histochemical identification of salivary mucins.

Authors:  G QUINTARELLI
Journal:  Ann N Y Acad Sci       Date:  1963-03-30       Impact factor: 5.691

5.  The specificity of the periodic acid-Schiff technique studied by a quantitative test-tube method.

Authors:  G J HOOGHWINKEL; G SMITS
Journal:  J Histochem Cytochem       Date:  1957-03       Impact factor: 2.479

6.  Progressive familial myoclonic epilepsy in three families: its clinical features and pathological basis.

Authors:  D G HARRIMAN; J H MILLAR; A C STEVENSON
Journal:  Brain       Date:  1955-09       Impact factor: 13.501

7.  Isolation and characterization of Lafora bodies in two cases of myoclonus epilepsy.

Authors:  S Yokoi; J Austin; F Witmer
Journal:  J Neuropathol Exp Neurol       Date:  1967-01       Impact factor: 3.685

8.  Problems of histochemical identification of carbohydrate-rich tissue components.

Authors:  K Meyer
Journal:  J Histochem Cytochem       Date:  1966-08       Impact factor: 2.479

9.  [Progressive myoclonus epilepsy with Lafora bodies. (Clinical, polygraphic and anatomic study of a case)].

Authors:  J Roger; H Gastaut; M Toga; R Soulayrol; H Régis; H Lob; A Tassinari; D Dubois; Y Poinso; E Mesdjian
Journal:  Rev Neurol (Paris)       Date:  1965-01       Impact factor: 2.607

10.  [Progressive myoclonus epilepsy with Lafora bodies. Clinical and polygraphic study. Anatomical ultrastructural verification].

Authors:  J Roger; H Gastaut; J Boudouresques; M Toga; D Dubois; H Lob
Journal:  Rev Neurol (Paris)       Date:  1967-03       Impact factor: 2.607

View more
  8 in total

1.  Corpora amylacea in the peripheral nerve axons.

Authors:  S Yagishita; Y Itoh; T Nakano
Journal:  Acta Neuropathol       Date:  1977-01-31       Impact factor: 17.088

2.  Correlation between ultrastructure and histochemistry of lafora bodies.

Authors:  J J Vanderhaeghen
Journal:  Acta Neuropathol       Date:  1971       Impact factor: 17.088

3.  Lafora's disease. An ultrastructural and histochemical study.

Authors:  S Ramón y Cajal; A Blanes; A Martinez; E Sáenz; M Gutierrez
Journal:  Acta Neuropathol       Date:  1974       Impact factor: 17.088

4.  [Recessive hereditary amyotrophic lateral sclerosis with "Lafora bodies" (author's transl)].

Authors:  H Orthner; P E Becker; D Müller
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1973-10-25

5.  [Histochemical reactions of strong acid radicals and especially phosphate].

Authors:  G Palladini
Journal:  Histochemie       Date:  1972

6.  [Histochemical studies on myoclonus bodies in progressive myoclonus epilepsy (Unverricht type)].

Authors:  R Schnabel; F Seitelberger
Journal:  Acta Neuropathol       Date:  1969-09-09       Impact factor: 17.088

7.  Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle.

Authors:  J J Martin; T de Barsy; F van Hoof; G Palladini
Journal:  Acta Neuropathol       Date:  1973-02-19       Impact factor: 17.088

8.  The retina in Lafora disease: light and electron microscopy.

Authors:  M Berard-Badier; J F Pellissier; D Gambarelli; T de Barsy; J Roger; M Toga
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1980
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.